Abacus FCF Advisors LLC Sells 23,857 Shares of DaVita Inc. $DVA

Abacus FCF Advisors LLC trimmed its stake in DaVita Inc. (NYSE:DVA) by 60.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,677 shares of the company’s stock after selling 23,857 shares during the period. Abacus FCF Advisors LLC’s holdings in DaVita were worth $2,083,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of DVA. Raymond James Financial Inc. boosted its position in DaVita by 6.8% during the 1st quarter. Raymond James Financial Inc. now owns 27,604 shares of the company’s stock valued at $4,223,000 after acquiring an additional 1,768 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of DaVita by 207.9% in the 1st quarter. Wellington Management Group LLP now owns 8,348 shares of the company’s stock valued at $1,277,000 after purchasing an additional 5,637 shares during the period. State of Wyoming boosted its position in shares of DaVita by 28.9% during the first quarter. State of Wyoming now owns 2,603 shares of the company’s stock valued at $398,000 after purchasing an additional 583 shares in the last quarter. Vident Advisory LLC purchased a new stake in DaVita in the first quarter worth $1,328,000. Finally, Baird Financial Group Inc. raised its holdings in DaVita by 322.9% in the first quarter. Baird Financial Group Inc. now owns 26,959 shares of the company’s stock worth $4,124,000 after purchasing an additional 20,584 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

DaVita stock opened at $113.40 on Tuesday. DaVita Inc. has a one year low of $112.54 and a one year high of $179.60. The stock has a fifty day moving average of $120.03 and a 200 day moving average of $130.43. The stock has a market cap of $8.01 billion, a PE ratio of 11.68, a price-to-earnings-growth ratio of 0.86 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Bank of America reduced their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 10th. Barclays cut their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday, October 30th. TD Cowen dropped their price target on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Cowen restated a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. Finally, Zacks Research upgraded DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $148.00.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.